AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting hopes that it could generate multibillion-dollar sales for the company. The biologic medicine, tozorakimab, is under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027….
My top 10 things to watch Monday, Aug. 3 1. Peace talks between the U.S. and Iran are back on the menu, so oil prices are falling. WTI crude is off more than 5%, trading below $80 a barrel this morning. Stock futures are higher across the board, led by the Dow . Within our…
AstraZeneca shares dropped as much as 7% after a report that the U.K.’s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion. AstraZeneca declined to comment. Bristol Myers Squibb didn’t immediately respond to a request to comment outside of…
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its purchase of Medarex in July added a key drug for metastic melanoma that’s in Phase III trials. The drug has possible multiple indications – industry jargon for its ability to treat more…
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the company. Most analysts estimate the trial miss wiped just 2-4% from their valuation models. Yet the shares lost roughly twice that in a single session, suggesting the market reaction reflected more than just the loss of one drug,…
Shares of AstraZeneca fell as much as 9% after a late stage clinical trial for an experimental heart disease failed to meet its target. The medicine, Wainua, did not reach its main goal of reducing deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo, the British drugmaker said in a press release…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,”…
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they’re already outlining their visions for the future of obesity drugs. At the American Diabetes Association’s Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots…
One of America’s largest pharmaceutical companies this week said it will partner with a Chinese drugmaker to test some of its experimental drugs and discover new ones, a deal that could mark the next phase of coordination across continents. Bristol Myers Squibb on Tuesday announced the potential multibillion-dollar partnership with one of China’s top drugmakers,…
Shares of AstraZeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug. An advisory panel for the U.S. Food and Drug Administration late Thursday voted 6-3 against AstraZeneca’s oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design. The FDA generally…
